December 6, 2024 05:32 PM EST
Startups
R&D

BioAge Labs scraps Phase 2 obe­si­ty tri­al just months af­ter IPO

Kyle LaHucik

Senior Reporter

BioAge Labs is scrap­ping a Phase 2 tri­al test­ing its an­ti-obe­si­ty drug, a few months af­ter its flashy $198 mil­lion ini­tial pub­lic …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Sage sues Bio­gen days af­ter $469M buy­out of­fer

An­oth­er US biotech emerges with drug can­di­date from Chi­na-based Keymed

Sion­na and Odyssey end JPM week with IPO fil­ings

FDA ap­proves As­traZeneca and Dai­ichi Sankyo’s ADC for breast can­cer de­spite lack of sur­vival ben­e­fit

Ozem­pic makes list for next round of Medicare drug price ne­go­ti­a­tions

sponsored

Fu­el­ing More Break­throughs: Man­u­fac­tur­ing In­no­va­tion to Ex­pand Gene Ther­a­py’s Reach

A service from the Financial Times